Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus

Beginning in May 2022, a novel cluster of monkeypox virus infections was detected in humans. This virus has spread rapidly to non-endemic countries, sparking global concern. Specific vaccines based on the vaccinia virus (VACV) have demonstrated high efficacy against monkeypox viruses in the past and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Syed Faraz, Sohail, Muhammad Saqib, Quadeer, Ahmed Abdul, McKay, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506226/
https://www.ncbi.nlm.nih.gov/pubmed/36146766
http://dx.doi.org/10.3390/v14091960
_version_ 1784796670367629312
author Ahmed, Syed Faraz
Sohail, Muhammad Saqib
Quadeer, Ahmed Abdul
McKay, Matthew R.
author_facet Ahmed, Syed Faraz
Sohail, Muhammad Saqib
Quadeer, Ahmed Abdul
McKay, Matthew R.
author_sort Ahmed, Syed Faraz
collection PubMed
description Beginning in May 2022, a novel cluster of monkeypox virus infections was detected in humans. This virus has spread rapidly to non-endemic countries, sparking global concern. Specific vaccines based on the vaccinia virus (VACV) have demonstrated high efficacy against monkeypox viruses in the past and are considered an important outbreak control measure. Viruses observed in the current outbreak carry distinct genetic variations that have the potential to affect vaccine-induced immune recognition. Here, by investigating genetic variation with respect to orthologous immunogenic vaccinia-virus proteins, we report data that anticipates immune responses induced by VACV-based vaccines, including the currently available MVA-BN and ACAM2000 vaccines, to remain highly cross-reactive against the newly observed monkeypox viruses.
format Online
Article
Text
id pubmed-9506226
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95062262022-09-24 Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus Ahmed, Syed Faraz Sohail, Muhammad Saqib Quadeer, Ahmed Abdul McKay, Matthew R. Viruses Article Beginning in May 2022, a novel cluster of monkeypox virus infections was detected in humans. This virus has spread rapidly to non-endemic countries, sparking global concern. Specific vaccines based on the vaccinia virus (VACV) have demonstrated high efficacy against monkeypox viruses in the past and are considered an important outbreak control measure. Viruses observed in the current outbreak carry distinct genetic variations that have the potential to affect vaccine-induced immune recognition. Here, by investigating genetic variation with respect to orthologous immunogenic vaccinia-virus proteins, we report data that anticipates immune responses induced by VACV-based vaccines, including the currently available MVA-BN and ACAM2000 vaccines, to remain highly cross-reactive against the newly observed monkeypox viruses. MDPI 2022-09-03 /pmc/articles/PMC9506226/ /pubmed/36146766 http://dx.doi.org/10.3390/v14091960 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ahmed, Syed Faraz
Sohail, Muhammad Saqib
Quadeer, Ahmed Abdul
McKay, Matthew R.
Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus
title Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus
title_full Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus
title_fullStr Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus
title_full_unstemmed Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus
title_short Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus
title_sort vaccinia-virus-based vaccines are expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506226/
https://www.ncbi.nlm.nih.gov/pubmed/36146766
http://dx.doi.org/10.3390/v14091960
work_keys_str_mv AT ahmedsyedfaraz vacciniavirusbasedvaccinesareexpectedtoelicithighlycrossreactiveimmunitytothe2022monkeypoxvirus
AT sohailmuhammadsaqib vacciniavirusbasedvaccinesareexpectedtoelicithighlycrossreactiveimmunitytothe2022monkeypoxvirus
AT quadeerahmedabdul vacciniavirusbasedvaccinesareexpectedtoelicithighlycrossreactiveimmunitytothe2022monkeypoxvirus
AT mckaymatthewr vacciniavirusbasedvaccinesareexpectedtoelicithighlycrossreactiveimmunitytothe2022monkeypoxvirus

Ejemplares similares